Health & Fitness
Health and Fitness
Health and Fitness
Mon, April 23, 2012Sun, April 22, 2012Sat, April 21, 2012Fri, April 20, 2012Thu, April 19, 2012Wed, April 18, 2012Tue, April 17, 2012Mon, April 16, 2012Sun, April 15, 2012Sat, April 14, 2012Fri, April 13, 2012Thu, April 12, 2012Wed, April 11, 2012Tue, April 10, 2012Mon, April 9, 2012Transcept Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
Published in Health and Fitness on Monday, April 16th 2012 at 13:46 GMT by Market Wire
Transcept Pharmaceuticals to Present at the BioCentury Future Leaders in the... -- POINT RICHMOND, Calif., April 16, 2012 /PRNewswire/ --
Transcept Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
POINT RICHMOND, Calif., April 16, 2012 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: [ TSPT ]), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, announced today that Transcept management is scheduled to present at the BioCentury Future Leaders in the Biotech Industry Conference in New York on April 20, 2012 at 8:30 a.m. ET.
(Logo: [ http://photos.prnewswire.com/prnh/20101102/SF93452LOGO ])
A live audio webcast and replay of this presentation may be accessed at [ http://www.media-server.com/m/p/dnf5o64x ] and on the Transcept Investor webpage at [ www.transcept.com ].
About Transcept
Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Intermezzo® (zolpidem tartrate) sublingual tablet C-IV is the first FDA approved Transcept product. Purdue holds commercialization and development rights for Intermezzo in the United States. Transcept is currently conducting a Phase 2 study of an investigational product, TO-2061, in patients with obsessive-compulsive disorder. For further information about Transcept, please visit [ www.transcept.com ].
Contact:
Transcept Pharmaceuticals, Inc.
Greg Mann
Sr. Director, Corporate Communications
(510) 215-3567
[ gmann@transcept.com ]
SOURCE Transcept Pharmaceuticals, Inc.
[ Back to top ] RELATED LINKS
[ http://www.transcept.com ]
